Lowest Price Guaranteed From USD 4,799
The antisense oligonucleotides market is estimated to be worth $2.5 billion in 2021 and is expected to grow at CAGR of 15% during the forecast period. Since the approval of Vitravene™ (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven antisense oligonucleotides drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso™ (duchenne muscular dystrophy, March 2020), Vyondys 53® (duchenne muscular dystrophy, December 2019) and Waylivra® (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019). Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, and even certain rare genetic disorders). Further, recent advances in antisense oligonucleotide chemistry have enabled the development and synthesis of specialized oligonucleotides, having improved safety profiles and better cell targeting capabilities. In fact, these advanced variants of antisense oligonucleotide-based therapeutic candidates are deemed to possess the potential to cater to the unmet need for effective treatment options for diseases that were previously considered difficult to treat.
Presently, several drug developers, along with ASO technology providers, are actively engaged in the development of various antisense therapy candidates. Innovation in this field of research is mostly focused on improving cell targeting ability, target affinity, nuclease resistance, and optimizing toxicity profiles of antisense oligonucleotide candidates. Several big pharma players have also demonstrated interest in antisense oligonucleotide therapeutics and are investing both time and capital in antisense oligonucleotides market. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by encouraging clinical trial results, the antisense oligonucleotide therapies market is poised to witness healthy market growth as multiple late stage drug candidates are approved and marketed during the forecast period.
Examples of key companies developing antisense oligonucleotides drugs (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences. This antisense oligonucleotides market report includes an easily searchable excel database of all the companies developing antisense oligonucleotide therapeutics, worldwide.
Several recent developments have taken place in the field of antisense oligonucleotides market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Antisense Oligonucleotides Market, 2020-2030” market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the antisense oligonucleotides market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in antisense oligonucleotides market.
In addition to other elements, the market research report includes:
The key objective of antisense oligonucleotides market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for antisense oligonucleotides market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of antisense oligonucleotides market for the forecast period 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] type of antisense molecule (RNA and DNA molecule) [B] different target indications (duchenne muscular dystrophy, spinal muscular atrophy, hereditary transthyretin-mediated (hATTR) amyloidosis, familial chylomicronemia syndrome, familial partial lipodystrophy, pouchitis, leber's congenital amaurosis, huntington’s disease and amyotrophic lateral sclerosis) [C] ASO generations (first-generation, second-generation and third-generation) [D] route of administration (intrathecal, intravenous, intravitreal, subcutaneous, and topical) [E] type of therapy (combination therapy and monotherapy) and [F] key geographical regions (US, UK, EU4, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this market research report are in USD, unless otherwise specified.